Home › Kidney Cancer (Renal Cell Carcinoma) › NCT05387863
Decision Aid (DA) for Renal Patients
Evaluation of a Decision Aid in the Treatment Planning of Small Renal Tumors
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter. * Patients scheduled for standard-of-care clinical exams with the NYU Urology Department Exclusion Criteria: * Stage IV cancer of any type * Inability to provide informed consent * Vulnerable subjects will not be recruited
About the study
The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit/harm estimates to patients and promote patient-centered treatment of renal tumors.
What is being tested
- Decision Aid (DA) Web Tool (other)
- Institutional Pamphlet (other)
Sponsor: NYU Langone Health · Participants: 40 · Started: Sep 12, 2022
Contact the study team
- Stella Kang, MD · Phone: 212-263-6246
- Samantha Sanger · Phone: 646-501-0086
Official record on ClinicalTrials.gov — NCT05387863
Locations in the U.S.
| New York | NYU Langone Health, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.